Guided Therapeutics (GTHP) Price to Sales (2021 - 2025)

Guided Therapeutics has disclosed Price to Sales across 5 years of filings, most recently posting 0.05 for Q4 2025.

• In Q4 2025, Price to Sales fell 99.39% year-over-year to 0.05; the TTM figure through Jun 2026 stood at 35.64 (up 30629.08% YoY), while the FY2025 annual figure was 22.88, down 96.71% from the prior year.
• Price to Sales came in at 0.05 for Q4 2025 at Guided Therapeutics, down from 0.22 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 5920.93 in Q3 2022 to a low of 0.05 in Q4 2025.
• Average Price to Sales over 5 years is 1161.25, with a median of 4.65 recorded in 2024.
• Year-over-year, Price to Sales tumbled 99.99% in 2023 and surged 3453.97% in 2024.
• Over 5 years, Price to Sales stood at 132.17 in 2021, then soared by 4379.7% to 5920.93 in 2022, then plunged by 100.0% to 0.23 in 2023, then surged by 3453.97% to 8.21 in 2024, then sank by 99.39% to 0.05 in 2025.
• Per Business Quant data, the three most recent Price to Sales figures were 0.05 in Q4 2025, 0.22 in Q3 2025, and 0.12 in Q2 2025.